UNSPSC 85815727: Introduction of immunosuppressive into central vein, percutaneous approach

This classification denotes the group of activities that yields a administrative intervention or procedure to introduction of immunosuppressive into central vein, percutaneous approach. This administrative intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 3E043WL

UNSPSC 85815727 Introduction of immunosuppressive into central vein, percutaneous approach is a Commodity code that describes a specific clinical procedure — intravenous infusion of immunosuppressive agents — yet the recent state and local opportunities tagged under it do not reflect this scope. Instead, the code shows little relevant recent activity aligned with its nominal definition. The five most recent state and local contract opportunities posted under this code span virtual urgent care services (Inland Empire Health Plan, RFI, due October 31, 2026), general medical services (DeKalb County, Georgia, RFP, due November 12, 2026), Program of All Inclusive Care for the Elderly operations (Nevada Health Authority, RFP, due December 10, 2026), cancer registry services (San Mateo County, RFP, due November 6, 2026), and handheld retinal screening devices and services (San Mateo County, RFP, due November 6, 2026). None of these solicitations involve immunosuppressive drug infusions or central-vein access procedures; they address preventive care, care coordination, screening, and registry support across health plans and public health systems in California, Georgia, and Nevada. The wide divergence between the UNSPSC code's clinical definition and the actual work being procured suggests either systematic miscoding of opportunities or limited applicability of this code to state and local purchasing.

Recent activity is geographically dispersed across California (Inland Empire Health Plan in San Bernardino County, San Mateo County), Georgia (DeKalb County), and Nevada (statewide PACE and rural care initiatives). Issuing bodies are primarily health authorities, county health systems, and regional health plans rather than hospitals or specialty clinics that might purchase immunosuppressive infusion services. The apparent mismatch between code definition and procurement reality indicates this code warrants careful review before investment; the source shows no state or local government solicitation for immunosuppressive drug administration or central-vein access procedures in the recent-opportunities block.